As the 2023 bid cycle begins, life sciences companies must understand how the Part D market is evolving and how health plans approach Part D formularies and benefit designs. This video series features Avalere leaders with deep expertise on opposing sides of Part D plan/manufacturer formulary negotiations. In the first video of the series, hear from Ryan Urgo and Neil Lund about:

• Membership trends in standalone prescription drug plans and Medicare Advantage prescription drug plans
• The rise in plan spending on specialty drugs in relation to brands and generics
• How these trends impact government payments, plan decision-making, and the push for program reform